Renovacor is a biotechnology firm dedicated to developing targeted treatments aimed at improving the lives of individuals and families grappling with genetically-driven cardiovascular diseases and other related conditions. Its primary therapeutic focus is on dilated cardiomyopathy (DCM) linked to mutations in the BCL2-associated athanogene 3 (BAG3) gene. The company's flagship product candidate, REN-001, is a sophisticated gene therapy employing a recombinant adeno-associated virus 9.